Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium

Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.